Anesthetic Effect - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
61 Pages - GMD12047
$2,000.00

Summary

Global Markets Direct’s, ‘Anesthetic Effect - Pipeline Review, H1 2014’, provides an overview of the Anesthetic Effect’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anesthetic Effect and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anesthetic Effect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anesthetic Effect pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anesthetic Effect Overview 7
Therapeutics Development 8
Pipeline Products for Anesthetic Effect - Overview 8
Pipeline Products for Anesthetic Effect - Comparative Analysis 9
Anesthetic Effect - Therapeutics under Development by Companies 10
Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes 12
Anesthetic Effect - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Anesthetic Effect - Products under Development by Companies 18
Anesthetic Effect - Products under Investigation by Universities/Institutes 19
Anesthetic Effect - Companies Involved in Therapeutics Development 20
Merck & Co., Inc. 20
Physica Pharma 21
Lipicard Technologies Limited 22
Maruishi Pharmaceutical Co., Ltd. 23
Sphaera Pharma Pvt. Ltd. 24
Advicenne Pharma SA 25
Sage Therapeutics 26
Anesthetic Effect - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 32
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 38
sugammadex sodium - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(tetracaine + oxymetazoline hydrochloride) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ADV-6209 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MR-04-A-3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LT-1121 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LT-1123 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SGE-202 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Ketamine Analogues - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Next Generation Anesthetic - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules for Anesthesia - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PHY-301 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Inhibit CGMP-Dependent Protein Kinase Ia for CNS Disorders - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Anesthetic Effect - Recent Pipeline Updates 51
Anesthetic Effect - Dormant Projects 52
Anesthetic Effect - Discontinued Products 53
Anesthetic Effect - Product Development Milestones 54
Featured News & Press Releases 54
Feb 11, 2014: PAION completes Phase II study with Remimazolam in indication anaesthesia 54
Oct 30, 2013: Paion Announced Recruitement of Ono's Hepatic Impairment Study with Remimazolam Is Completed 54
Aug 07, 2013: gIcare Pharma begins phase IIa trial of GIC-1001 for colonic analgesia 55
Nov 05, 2012: Paion's Partner Ono Pharma Intiates Phase II/III Study With Short-acting Anaesthetic/Sedative Remimazolam In Japan 55
Oct 30, 2012: Powder Pharma Submits Application For FDA Approval Of Zingo Manufacturing Facility In New Hong Kong 56
May 14, 2012: Ono Pharma Announces Phase II Study Results Of ONO-2745/CNS 7056 56
Oct 14, 2011: APP Pharmaceuticals Announces Increased Availability Of APP Diprivan And APP Propofol 1% 57
May 31, 2011: PAION Receives Second Milestone Payment Of $3m From Ono Pharmaceutical Through Start Of Japanese Phase II With Remimazolam 57
Nov 22, 2010: PAION Reports Positive Results Of CNS 7056 In Phase IIb Study In Colonoscopy 58
Sep 27, 2010: PAION Completes Phase IIb Study With CNS 7056 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Anesthetic Effect, H1 2014 8
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Comparative Analysis by Unknown Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Anesthetic Effect - Pipeline by Merck & Co., Inc., H1 2014 20
Anesthetic Effect - Pipeline by Physica Pharma, H1 2014 21
Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H1 2014 22
Anesthetic Effect - Pipeline by Maruishi Pharmaceutical Co., Ltd., H1 2014 23
Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2014 24
Anesthetic Effect - Pipeline by Advicenne Pharma SA, H1 2014 25
Anesthetic Effect - Pipeline by Sage Therapeutics, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Assessment by Combination Products, H1 2014 28
Number of Products by Stage and Target, H1 2014 31
Number of Products by Stage and Mechanism of Action, H1 2014 34
Number of Products by Stage and Route of Administration, H1 2014 36
Number of Products by Stage and Molecule Type, H1 2014 37
Anesthetic Effect Therapeutics - Recent Pipeline Updates, H1 2014 51
Anesthetic Effect - Dormant Projects, H1 2014 52
Anesthetic Effect - Discontinued Products, H1 2014 53

List of Figures
Number of Products under Development for Anesthetic Effect, H1 2014 8
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Comparative Analysis by Unknown Stage Development, H1 2014 17
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 29
Number of Products by Stage and Top 10 Target, H1 2014 30
Number of Products by Top 10 Mechanism of Action, H1 2014 32
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 33
Number of Products by Top 10 Route of Administration, H1 2014 35
Number of Products by Stage and Top 10 Route of Administration, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax